Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 9:21 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 2,911 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Event Clear all
Completed Not applicable Interventional

A Study on the Rate of Opportunistic (AIDS-Related) Infections Among HIV-Positive Children Who Have Stopped Taking Their OI Preventive Medications

NCT00001078
View directory record Official record
Conditions
HIV Infections
Interventions
Hepatitis A Vaccine (Inactivated)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 21 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
47
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2011 · Synced Nov 2, 2026, 9:21 AM EST
Recruiting Phase 2 Interventional

Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Progression on or Following First-Line Immunotherapy Maintenance

NCT07594015
View directory record Official record
Conditions
Recurrent Endometrial Cancer
Interventions
Pembrolizumab, Lenvatinib
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Nov 2, 2026, 9:21 AM EST
Completed Not applicable Interventional Results available

Treatment for Affect Dimensions

NCT03439748
View directory record Official record
Conditions
Depression, Anxiety
Interventions
Positive Affect Treatment, Negative Affect Treatment
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Los Angeles, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Nov 2, 2026, 9:21 AM EST
Completed No phase listed Observational

Coronary Heart Disease Incidence: Depression & Inflammation Risk

NCT00241774
View directory record Official record
Conditions
Cardiovascular Diseases, Coronary Disease, Heart Diseases, Depression, Inflammation
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
3,227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2016 · Synced Nov 2, 2026, 9:21 AM EST
Completed No phase listed Observational

Alirocumab and Ischemic Risk in Atherosclerotic Cardiovascular Disease (ASCVD)

NCT07615179
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events
Interventions
Alirocumab, Comparator: No PCSK9i Therapy (either mAb or siRNA)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
4,545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Nov 2, 2026, 9:21 AM EST
Recruiting Phase 1 Interventional

Hydrogen's Feasibility and Safety as a Therapy in ECPR

NCT05574296
View directory record Official record
Conditions
Cardiac Arrest, Extracorporeal Membrane Oxygenation, Reperfusion Injury
Interventions
Hydrogen, Usual care
Drug · Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Not listed
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • Kansas City, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Nov 2, 2026, 9:21 AM EST
Recruiting Not applicable Interventional

Safety Evaluation of MODI, an Insulin Titration Algorithm, in Adults With Diabetes

NCT07599982
View directory record Official record
Conditions
Type 1 Diabetes (T1D), Type 2 Diabetes (T2D)
Interventions
MODI Algorithm
Device
Lead sponsor
DreaMed Diabetes
Industry
Eligibility
18 Years to 80 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
6
States / cities
Baltimore, Maryland • Detroit, Michigan • Albany, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Nov 2, 2026, 9:21 AM EST
Recruiting Phase 2 Interventional

Cannabinoid Interactions With Central and Peripheral Pain Mechanisms in Osteoarthritis of the Knee

NCT04992624
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis of the Knee
Interventions
Placebo, Cannabidiol (CBD), Tetrahydrocannabinol (Marinol® or generic equivalent (e.g., dronabinol)
Drug
Lead sponsor
Steven E Harte, PhD
Other
Eligibility
21 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Nov 2, 2026, 9:21 AM EST
Completed Not applicable Interventional Results available

A Tailored, Peer-delivered Intervention to Reduce Recurring Opioid Overdoses

NCT02922959
View directory record Official record
Conditions
Drug Overdose, Opioid-Related Disorders, Drug Addiction, Drug Abuse, Substance Abuse
Interventions
Peer Intervention, naloxone nasal spray kit, Personally-tailored opioid overdose prevention education (information packet)
Behavioral · Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 24, 2020 · Synced Nov 2, 2026, 9:21 AM EST
Recruiting Phase 4 Interventional Accepts healthy volunteers

Elucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia

NCT07284290
View directory record Official record
Conditions
Dementia With Lewy Bodies, Parkinson Disease Dementia, Healthy Controls
Interventions
Syn-One skin biopsy, Multi modal MRI, Assessment of dynamic EEG features over 48-hour periods across all study aims, Plasma biomarkers, Galantamine HBr extended-release 8mg capsules (8mg ER).
Procedure · Diagnostic Test · Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
50 Years to 89 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Nov 2, 2026, 9:21 AM EST
Active, not recruiting Phase 3 Interventional

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

NCT06461897
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Upadacitinib, Dupilumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 11 Years
Enrollment
699 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
31
States / cities
Little Rock, Arkansas • Palo Alto, California • Sacramento, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 2, 2026, 9:21 AM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Smart Eyewear to Automatically Detect Drug Delivery Events

NCT05184660
View directory record Official record
Conditions
Smart Eyewear
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Nov 2, 2026, 9:21 AM EST
Completed Not applicable Interventional

Brief Inpatient Psychotherapy for Depression

NCT03091582
View directory record Official record
Conditions
Depression
Interventions
Cognitive factors, Behavioral factors, Increase engagement of pleasant events
Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2018 · Synced Nov 2, 2026, 9:21 AM EST
Active, not recruiting Not applicable Interventional

Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies

NCT05370469
View directory record Official record
Conditions
Lung Cancer, EGFR Gene Mutation, EGFR, ALK Gene Mutation, RET Gene Mutation, MET Gene Mutation, KRAS Mutation-Related Tumors, BRAF, ROS1 Gene Mutation
Interventions
Sensus Smartwatch Application, RX Cap, Fitbit Sense, Surveys
Other · Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Nov 2, 2026, 9:21 AM EST
Completed Phase 4 Interventional Results available

Electrophysiological Effects of Guanfacine Extended Release in Attention Deficit Hyperactivity Disorder (ADHD)

NCT01069523
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Guanfacine Extended Release, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
6 Years to 12 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Nov 2, 2026, 9:21 AM EST
Completed Phase 2 Interventional Results available

Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies

NCT04552288
View directory record Official record
Conditions
Solid Tumor, Solid Carcinoma, Solid Tumor, Adult, Hematologic Malignancy
Interventions
Benralizumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 85 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Nov 2, 2026, 9:21 AM EST
Active, not recruiting Phase 3 Interventional

A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event

NCT07000123
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
AZD0780, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
3,103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
101
States / cities
Huntsville, Alabama • Irondale, Alabama • Mobile, Alabama + 92 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Nov 2, 2026, 9:21 AM EST
Completed Not applicable Interventional

Gratitude Intervention for Cardiac Rehabilitation Patients

NCT04314583
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Attention Control, Gratitude Journaling
Behavioral
Lead sponsor
Martha Biddle
Other
Eligibility
18 Years to 100 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Nov 2, 2026, 9:21 AM EST
Completed Phase 3 Interventional Results available

Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers

NCT00960869
View directory record Official record
Conditions
Gastric Ulcer
Interventions
PA32540, EC-Aspirin 325 mg
Drug
Lead sponsor
POZEN
Industry
Eligibility
55 Years and older
Enrollment
519 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Nov 2, 2026, 9:21 AM EST
Terminated Not applicable Interventional

Trial of Oral Lenalidomide Stewardship Program for Veterans

NCT04835220
View directory record Official record
Conditions
Medication Compliance
Interventions
Telehealth Calls
Other
Lead sponsor
W.G. Bill Hefner Medical Center
Federal
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Salisbury, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Nov 2, 2026, 9:21 AM EST
Completed Phase 2 Interventional Results available

A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

NCT03940703
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Tepotinib, Osimertinib
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
49
States / cities
Yuma, Arizona • Fountain Valley, California • Long Beach, California + 43 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Nov 2, 2026, 9:21 AM EST
Completed Not applicable Interventional Results available

Pragmatic Comparative Effectiveness Trial of Evidence-based, On-demand, Digital Behavioral Treatments for Chronic Pain

NCT04933474
View directory record Official record
Conditions
Chronic Pain
Interventions
painTRAINER®, Skills-Based VR
Behavioral · Device
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
13 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Nov 2, 2026, 9:21 AM EST
Completed Not applicable Interventional Results available

Compression Stocking Use in Shoulder Arthroscopy in Beach Chair

NCT01996813
View directory record Official record
Conditions
Obesity, Shoulder Impingement
Interventions
Thigh-high compression stockings
Device
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Nov 2, 2026, 9:21 AM EST
Completed Phase 4 Interventional Results available

Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)

NCT04363697
View directory record Official record
Conditions
Acute Heart Failure, Heart Failure
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
The TIMI Study Group
Other
Eligibility
18 Years and older
Enrollment
2,401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Nov 2, 2026, 9:21 AM EST